Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Market Cap | 356.831 Million | Shares Outstanding | 61.101 Million | Avg 30-day Volume | 68.838 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.24 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -31.459 Million |
Price to Book Value | 0.1312 | Operating Margin | 0.0 | Enterprise Value | -21.037 Million |
Current Ratio | 4.51 | EPS Growth | 0.037 | Quick Ratio | 4.425 |
1 Yr BETA | -0.1803 | 52-week High/Low | 6.76 / 0.34 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -14.4104 | Altman Z-Score | -11.7307 | Free Cash Flow to Firm | -15.9 Million |
Earnings Report | 2022-11-07 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
7,800 | 2022-06-24 | 2 | |
|
7,800 | 2022-06-24 | 1 | |
|
11,700 | 2022-06-24 | 2 | |
|
7,800 | 2022-06-24 | 1 | |
|
7,800 | 2022-06-24 | 1 | |
KOLEAN CHAD J CHIEF FINANCIAL OFFICER |
|
240 | 2022-02-24 | 3 |
CARUSO JAMES V PRESIDENT AND CEO |
|
1,419,000 | 2022-01-25 | 1 |
ELEFANT DOV CHIEF FINANCIAL OFFICER |
|
422,000 | 2022-01-25 | 1 |
LONGCOR JARROD CHIEF BUSINESS OFFICER |
|
475,000 | 2022-01-25 | 1 |
FRIEND JOHN E. II CHIEF MEDICAL OFFICER |
|
330,000 | 2021-03-04 | 0 |
|
0 | 2020-06-24 | 0 | |
GRACHEV IGOR D CHIEF MEDICAL OFFICER |
|
0 | 2020-01-06 | 0 |
BERNHARDT CHARLES THOMAS III INTERIM CFO |
|
0 | 2019-03-09 | 0 |
POSNER BRIAN M CHIEF FINANCIAL OFFICER |
|
0 | 2019-01-17 | 0 |
HAMILL JOHN P. INTERIM CFO |
|
0 | 2017-09-05 | 0 |
|
No longer subject to file | 2016-08-09 | 0 | |
WEICHERT JAMEY P CHIEF SCIENTIFIC OFFICER |
|
0 | 2016-05-12 | 0 |
|
234,742 | 2016-04-20 | 0 | |
|
469,484 | 2016-04-14 | 0 | |
|
No longer subject to file | 2015-12-30 | 0 | |
GENN JOHN PATRICK VP OF BUSINESS DEVELOPMENT |
|
0 | 2015-02-26 | 0 |
|
1,142,368 | 2015-02-03 | 0 | |
SZAKACS CAMERON VP OF CLINICAL DEVELOPMENT |
|
0 | 2014-11-24 | 0 |
PEDDER SIMON PRESIDENT AND CEO |
|
290,878 | 2014-08-20 | 0 |
CORMORANT ASSET MANAGEMENT, LLC |
|
530,000 | 2014-08-15 | 0 |
MCNEIL KATHRYN M SEE REMARKS |
|
0 | 2014-08-14 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-08-01 18:01:54 -0400 | 2022-06-24 | A | 11,700 | a | 11,700 | direct | ||||||||||
2022-08-01 18:01:38 -0400 | 2022-06-24 | A | 7,800 | a | 7,800 | direct | ||||||||||
2022-08-01 18:01:20 -0400 | 2022-06-24 | A | 7,800 | a | 7,800 | direct | ||||||||||
2022-08-01 18:00:54 -0400 | 2022-06-24 | A | 7,800 | a | 7,800 | direct | ||||||||||
2022-08-01 18:00:52 -0400 | 2022-06-24 | A | 7,800 | a | 7,800 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 22:15:04 UTC | -7.6264 | 9.9464 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 21:45:04 UTC | -7.673 | 9.993 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 21:15:04 UTC | -7.673 | 9.993 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 20:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 20:15:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 19:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 19:15:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 18:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 18:15:05 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 17:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 17:15:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 16:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 16:15:03 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 15:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 15:15:05 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 14:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 14:15:05 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 13:45:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 13:15:04 UTC | -7.3654 | 9.6854 | 100000 |
CELLECTAR BIOSCIENCES INC CLRB | 2022-08-18 12:45:05 UTC | -7.3654 | 9.6854 | 100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|